159.

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

PUBLIC HEALTH SERVICE

13 May 1959

National Institute of Mental Health
Addiction Research Center
U.S. Public Health Service Hospital
Lexington, Kentucky

(b)(6)

I am enclosing reports on d-dihydro-LSD, l-Methyl-d-lysergic acid butanolamide, and elymoclavine. The first two are materials received from the Sandoz Company. Neither seems of particularly great interest at the moment. D-dihydro-LSD is about one-third as potent as LSD, whereas 1-Methyl-d-lysergic acid butanolamide is not a psychotomimetic. Elymoclavine is of some interest since, like agroclavine, it induces sedative effects in man, and may in fact be more potent than agroclavine or Lilly 23194.

We plan to do a dose-effect curve with this latter material, provided an additional supply can be obtained, and to compare it directly with secobarbital.

Yours very sincerely,

Harris Isbell

Harris Isbell, M.D.
Director

HI:rn

Enclosures

D-247